At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 152 enrolled
Drug / intervention
Phenazopyridinedrug
Likely dose
Phenazopyridine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Phenazopyridine on Prolapse Surgery Voiding Trials
In Brief
A Phase 3 clinical trial evaluating Phenazopyridine for Urinary Retention Postoperative. Completed, enrolled 152 participants across 1 site.
Detailed Summary
To determine if phenazopyridine reduces the rate of postoperative urinary retention after pelvic organ prolapse surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Retention Postoperative
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
First PostedFeb 2017
Primary CompletionAug 2018
Study CompletionFeb 2019
TodayJul 2026
First PostedFeb 27, 2017
Enrollment StartFeb 1, 2017
Primary CompletionAug 28, 2018
Study CompletionFeb 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.3 years ago
Interventions
Phenazopyridinedrug
Phenazopyridine 200 mg on morning of postoperative day 1